Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOKFree Report) in a research report released on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of EVOK opened at $1.25 on Friday. Evoke Pharma has a 1 year low of $0.92 and a 1 year high of $5.96. The company has a market cap of $4.16 million, a price-to-earnings ratio of -0.55 and a beta of 0.28. The company has a debt-to-equity ratio of 9.29, a quick ratio of 3.27 and a current ratio of 3.50. The firm has a fifty day moving average of $1.21 and a 200-day moving average of $1.45.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Read More

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.